KALV Insider Trading Activity and SEC Form 4 Filings
KALV insider trading summary
Over the past 12 months, insiders at KalVista Pharmaceuticals, Inc. (KALV) reported 32 sales worth $3.0M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $3.0M.
Latest KALV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 27, 2026 | Christopher Yea | Chief Development Officer | Sell | $905K (33,800 @ $26.78) |
| May 26, 2026 | Paul K. Audhya | Chief Medical Officer | Sell | $60K (2,239 @ $26.78) |
| May 26, 2026 | Nicole Sweeny | Chief Commercial Officer | Sell | $40K (1,489 @ $26.78) |
| May 26, 2026 | Christopher Yea | Chief Development Officer | Sell | $53K (1,966 @ $26.78) |
| May 22, 2026 | Christopher Yea | Chief Development Officer | Sell | $63K (2,358 @ $26.78) |
| May 22, 2026 | Benjamin L Palleiko | Chief Executive Officer | Sell | $293K (10,926 @ $26.78) |
| May 22, 2026 | Paul K. Audhya | Chief Medical Officer | Sell | $72K (2,685 @ $26.78) |
| May 22, 2026 | Nicole Sweeny | Chief Commercial Officer | Sell | $50K (1,861 @ $26.78) |
| May 22, 2026 | Brian Piekos | Chief Financial Officer | Sell | $40K (1,489 @ $26.78) |
| May 18, 2026 | Benjamin L Palleiko | Chief Executive Officer | Sell | $30K (1,129 @ $26.76) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.